Showing results (401-410 of 484) with videos related to

Sort By:
Pageof 49
The Journal of Infectious Diseases|January 1, 1987
B subunit-whole cell and whole cell-only oral vaccines against cholera: studies on reactogenicity and immunogenicityJ D Clemens, B F Stanton, J Chakraborty, et al.
Mymensingh Medical Journal : MMJ|September 3, 2015
Immediate Clinical and Echocardiographic Outcome of Percutaneous Transvenous Mitral Commissurotomy for Patients of Mitral Stenosis with Atrial FibrillationM T Rahman, M M Rahman, M M Islam, et al.
Lancet (London, England)|June 18, 1988
Impact of B subunit killed whole-cell and killed whole-cell-only oral vaccines against cholera upon treated diarrhoeal illness and mortality in an area endemic for choleraJ D Clemens, D A Sack, J R Harris, et al.
Lancet (London, England)|February 3, 1990
Field trial of oral cholera vaccines in Bangladesh: results from three-year follow-upJ D Clemens, D A Sack, J R Harris, et al.
Vaccine|October 1, 1990
Field trial of oral cholera vaccines in Bangladesh: evaluation of anti-bacterial and anti-toxic breast-milk immunity in response to ingestion of the vaccinesJ D Clemens, D A Sack, J Chakraborty, et al.
Fundamental and Applied Toxicology : Official Journal of the Society of Toxicology|November 1, 1995
The CAT-Tox (L) assay: a sensitive and specific measure of stress-induced transcription in transformed human liver cellsM D Todd, M J Lee, J L Williams, et al.
Annals of Surgery|July 1, 1981
Effectiveness of steroid/antibiotic treatment in primates administered LD100 Escherichia coliL B Hinshaw, B K Beller-Todd, L T Archer, et al.
The American Journal of Medicine|March 1, 1990
Coronary flow reserve, esophageal motility, and chest pain in patients with angiographically normal coronary arteriesR O Cannon, E L Cattau, P N Yakshe, et al.
Archives of Internal Medicine|March 1, 1989
Pulmonary disease in progressive systemic sclerosis. A complication of gastroesophageal reflux and occult aspiration?D A Johnson, W E Drane, J Curran, et al.
The American Journal of Gastroenterology|February 24, 2001
Esomeprazole once daily for 6 months is effective therapy for maintaining healed erosive esophagitis and for controlling gastroesophageal reflux disease symptoms: a randomized, double-blind, placebo-controlled study of efficacy and safetyD A Johnson, S B Benjamin, N B Vakil, et al.
Pageof 49